Cargando…
Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications
The incidence of heart failure with preserved ejection fraction (HFpEF) is increasing and its challenging diagnosis and management combines clinical, imagistic and biological data. Natriuretic peptides (NPs) are hormones secreted in response to myocardial stretch that, by increasing cyclic guanosine...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600439/ https://www.ncbi.nlm.nih.gov/pubmed/31142058 http://dx.doi.org/10.3390/ijms20112629 |
_version_ | 1783431116479266816 |
---|---|
author | Tanase, Daniela Maria Radu, Smaranda Al Shurbaji, Sinziana Baroi, Genoveva Livia Florida Costea, Claudia Turliuc, Mihaela Dana Ouatu, Anca Floria, Mariana |
author_facet | Tanase, Daniela Maria Radu, Smaranda Al Shurbaji, Sinziana Baroi, Genoveva Livia Florida Costea, Claudia Turliuc, Mihaela Dana Ouatu, Anca Floria, Mariana |
author_sort | Tanase, Daniela Maria |
collection | PubMed |
description | The incidence of heart failure with preserved ejection fraction (HFpEF) is increasing and its challenging diagnosis and management combines clinical, imagistic and biological data. Natriuretic peptides (NPs) are hormones secreted in response to myocardial stretch that, by increasing cyclic guanosine monophosphate (cGMP), counteract myocardial fibrosis and hypertrophy, increase natriuresis and determine vasodilatation. While their role in HFpEF is controversial, most authors focused on b-type natriuretic peptides (BNPs) and agreed that patients may show lower levels. In this setting, newer molecules with an increased specificity, such as middle-region pro-atrial natriuretic peptide (MR-proANP), emerged as promising markers. Augmenting NP levels, either by NP analogs or breakdown inhibition, could offer a new therapeutic target in HFpEF (already approved in their reduced EF counterparts) by increasing the deficient cGMP levels found in patients. Importantly, these peptides also retain their prognostic value. This narrative review focuses on NPs’ physiology, diagnosis, therapeutic and prognostic implication in HFpEF. |
format | Online Article Text |
id | pubmed-6600439 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-66004392019-07-16 Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications Tanase, Daniela Maria Radu, Smaranda Al Shurbaji, Sinziana Baroi, Genoveva Livia Florida Costea, Claudia Turliuc, Mihaela Dana Ouatu, Anca Floria, Mariana Int J Mol Sci Review The incidence of heart failure with preserved ejection fraction (HFpEF) is increasing and its challenging diagnosis and management combines clinical, imagistic and biological data. Natriuretic peptides (NPs) are hormones secreted in response to myocardial stretch that, by increasing cyclic guanosine monophosphate (cGMP), counteract myocardial fibrosis and hypertrophy, increase natriuresis and determine vasodilatation. While their role in HFpEF is controversial, most authors focused on b-type natriuretic peptides (BNPs) and agreed that patients may show lower levels. In this setting, newer molecules with an increased specificity, such as middle-region pro-atrial natriuretic peptide (MR-proANP), emerged as promising markers. Augmenting NP levels, either by NP analogs or breakdown inhibition, could offer a new therapeutic target in HFpEF (already approved in their reduced EF counterparts) by increasing the deficient cGMP levels found in patients. Importantly, these peptides also retain their prognostic value. This narrative review focuses on NPs’ physiology, diagnosis, therapeutic and prognostic implication in HFpEF. MDPI 2019-05-28 /pmc/articles/PMC6600439/ /pubmed/31142058 http://dx.doi.org/10.3390/ijms20112629 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Tanase, Daniela Maria Radu, Smaranda Al Shurbaji, Sinziana Baroi, Genoveva Livia Florida Costea, Claudia Turliuc, Mihaela Dana Ouatu, Anca Floria, Mariana Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications |
title | Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications |
title_full | Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications |
title_fullStr | Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications |
title_full_unstemmed | Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications |
title_short | Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications |
title_sort | natriuretic peptides in heart failure with preserved left ventricular ejection fraction: from molecular evidences to clinical implications |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600439/ https://www.ncbi.nlm.nih.gov/pubmed/31142058 http://dx.doi.org/10.3390/ijms20112629 |
work_keys_str_mv | AT tanasedanielamaria natriureticpeptidesinheartfailurewithpreservedleftventricularejectionfractionfrommolecularevidencestoclinicalimplications AT radusmaranda natriureticpeptidesinheartfailurewithpreservedleftventricularejectionfractionfrommolecularevidencestoclinicalimplications AT alshurbajisinziana natriureticpeptidesinheartfailurewithpreservedleftventricularejectionfractionfrommolecularevidencestoclinicalimplications AT baroigenovevalivia natriureticpeptidesinheartfailurewithpreservedleftventricularejectionfractionfrommolecularevidencestoclinicalimplications AT floridacosteaclaudia natriureticpeptidesinheartfailurewithpreservedleftventricularejectionfractionfrommolecularevidencestoclinicalimplications AT turliucmihaeladana natriureticpeptidesinheartfailurewithpreservedleftventricularejectionfractionfrommolecularevidencestoclinicalimplications AT ouatuanca natriureticpeptidesinheartfailurewithpreservedleftventricularejectionfractionfrommolecularevidencestoclinicalimplications AT floriamariana natriureticpeptidesinheartfailurewithpreservedleftventricularejectionfractionfrommolecularevidencestoclinicalimplications |